Ardelyx presents data on IBSRELA at ACG annual scientific meeting

Ardelyx (ARDX), announced that the company presented data supporting the company’s first-in-class retainagogue, IBSRELA at the American College of Gastroenterology’s, ACG, Annual Scientific Meeting, now underway in Phoenix. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation, IBS-C, in adults. Poster: “Treatment Satisfaction With Tenapanor: Real-World Survey of Patients With Irritable Bowel Syndrome With Constipation,” reports data from a real-world survey of patients receiving tenapanor for the treatment of IBS-C. Poster: “Tenapanor Improves Abdominal Bloating Symptoms in Patients With IBS-C Experiencing Moderate to Severe Bloating,” demonstrates, based on the Phase 3 T3MPO-1 and T3MPO-2 studies, that tenapanor may be effective in reducing bloating for patients with IBS-C and that a clinically meaningful reduction in bloating can be experienced as early as week one of treatment onset and sustained through the duration of treatment. Poster: “Reduction in Gastrointestinal Visits and Portal Messaging Following Tenapanor Initiation for Community Gastrointestinal Patients,” reports data from an ongoing electronic health record study to understand real-world use and outcomes of IBS-C medications in community gastrointestinal practices.